(Q34285880)

1 August 2017

title

Is breast cancer survival improving? (English)

1 reference

1 August 2017

1 reference

Sharon H Giordano

1

0 references

Gabriel N Hortobagyi

series ordinal

6

object named as

Gabriel N Hortobagyi

1 reference

1 August 2017

2

Aman U Buzdar

1 reference

1 August 2017

Terry L Smith

3

1 reference

1 August 2017

Shu-Wan Kau

series ordinal

4

1 reference

1 August 2017

Ying Yang

series ordinal

5

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

1 August 2017

1 reference

1 August 2017

volume

100

1 reference

1 August 2017

issue

1

1 reference

1 August 2017

page(s)

44-52

1 reference

1 August 2017

cites work

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11859

7 January 2021

Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11859

7 January 2021

1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11859

7 January 2021

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11859

7 January 2021

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11859

7 January 2021

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11859

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11859

7 January 2021

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11859

7 January 2021

Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11859

7 January 2021

Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11859

7 January 2021

Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11859

7 January 2021

A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11859

7 January 2021

Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11859

7 January 2021

Identifiers

DOI

10.1002/CNCR.11859

1 reference

1 August 2017

1 reference